Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol. 2016 12 08; 9(1):137.

View in: PubMed

subject areas

Aged
Aged, 80 and over
Bridged-Ring Compounds
Female
fms-Like Tyrosine Kinase 3
Humans
Janus Kinase 2
Male
Maximum Tolerated Dose
Middle Aged
Myeloproliferative Disorders
Organ Size
Primary Myelofibrosis
Protein Kinase Inhibitors
Pyrimidines
Treatment Outcome

authors with profiles

Olatoyosi Odenike